Nedosiran

尼德司瑞

Report date: 2024/08/01 16:14:54
NME

Base Information

Drug NameNedosiran
Drug Alias NameRivflozaDCR-PHssDCR-PHXCDRNA-16.1DCR-L1360 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceL-lactate dehydrogenase A chain degraders
TargetsL-lactate dehydrogenase A chain
Therapy Area/IndicationsPrimary Hyperoxaluria Type 1Kidney Failure, ChronicHyperoxaluria, Primary +[4] 
Global Approved IndicationsHyperoxaluria
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/09/29
Country/TerritoryCanadaUnited StatesPoland +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDicerna Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk IncNovo Nordisk A/SDicerna Pharmaceuticals Inc +[4] 
Inactive CompaniesN/A
Active IndicationsPrimary Hyperoxaluria Type 1Kidney Failure, ChronicHyperoxaluria, Primary +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A